瑞银发表研究报告指，康方生物(9926.HK)核心产品AK112（ivonescimab）在非小细胞肺癌（NSCLC） 外的适应症展现巨大潜力，除NSCLC的6项适应症外，公司另启动6项三期临床试验，覆盖胆管癌、三 阴性乳腺癌、胰腺癌等一线治疗领域，适应症广度居同类药物之首。瑞银指，该药物自今年1月纳入国 家医保目录后销售快速增长，5月获批NSCLC一线治疗新适应症，有望通过2025年医保谈判进一步贡献 增量收入，将AK112在中国及全球销售高峰值上调至12亿及146亿美元，重申买入评级，并将目标价从 112.1港元大幅上调至197.5港元。 ...

瑞银重申康方生物买入评级 目标价一举升至197.5港元 金十数据8月1日讯，瑞银发表研究报告指，康方生物(09926.HK)核心产品AK112（ivonescimab）在非小 细胞肺癌（NSCLC）外的适应症展现巨大潜力，除NSCLC的6项适应症外，公司另启动6项三期临床试 验，覆盖胆管癌、三阴性乳腺癌、胰腺癌等一线治疗领域，适应症广度居同类药物之首。瑞银指，该药 物自今年1月纳入国家医保目录后销售快速增长，5月获批NSCLC一线治疗新适应症，有望通过2025年 医保谈判进一步贡献增量收入，将AK112在中国及全球销售高峰值上调至12亿及146亿美元，重申买入 评级，并将目标价从112.1港元大幅上调至197.5港元。 ...

Investment Rating - The report rates the pharmaceutical industry as "Overweight," indicating a positive outlook for the sector compared to the overall market performance [4][27]. Core Insights - The pharmaceutical sector saw a weekly increase of 3.6%, outperforming the Shanghai Composite Index, which rose by 1.4% [4][5]. - The report highlights the introduction of supportive policies for innovative drugs and high-end medical devices, including a comprehensive support system for innovative drug development, access, usage, and payment [4][12]. - The negotiation for the 2025 National Medical Insurance Drug List has officially started, with plans to include innovative drugs in commercial health insurance for the first time [4][13]. - AstraZeneca and Summit are reportedly negotiating a deal worth over $15 billion for the drug AK112, indicating significant activity in the innovative drug market [4][16]. - The report emphasizes the growth in revenue and licensing deals for innovative drugs, suggesting a trend towards broader market expansion [4]. Market Performance - The pharmaceutical sector's overall valuation stands at 29.8 times PE (2025E), ranking 6th among 31 primary industries [4][11]. - The performance of various sub-sectors includes: - Raw materials (+5.8%) - Chemical preparations (+4.9%) - Other biological products (+8.3%) - Medical devices (-0.2%) [4][7]. Key Events - On July 1, the National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, outlining 16 specific initiatives [4][12]. - The National Medical Products Administration announced measures to support the innovation of high-end medical devices, focusing on key areas such as medical robots and AI medical devices [4][13]. - Longcheng Gaoxin announced plans to issue H shares and list on the Hong Kong Stock Exchange, enhancing its international brand image [4][15].